JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

# A REPORT ON DIAGNOSIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

**Name of Authors-**
**Navneet Raj* Tushar Chauhan, Siya Sharma, Naresh Kumar**
Research Scholar at Dreamz College of Pharmacy, Distt. Mandi (H.P.)-175036

## ABSTRACT

The complicated autoimmune disease known as systemic lupus erythematosus (SLE) is typified by a wide range of clinical symptoms and an unpredictable course of the illness. The purpose of this study is to provide an overview of current methods for SLE diagnosis and treatment. Antinuclear antibody (ANA) screening and particular autoantibody assessments are among the laboratory tests used in the diagnosis process, which combined assist distinguish SLE from other autoimmune diseases. Initiating proper care and enhancing patient outcomes require an early diagnosis.The main goals of treatment plans are to manage symptoms and stop disease flare-ups. Immunosuppressants and corticosteroids are standard treatments that are vital for treating severe symptoms.

**Keywords-** Overview, Current Methods, Screening, Outcomes.

## 1.INTRODUCTION

### 1.1 Systemic Lupus Erythematosus (SLE)

A Systemics Lupus erythrmatosus (SLE) is an autoimmune disease with specifics antinuclear antibodies. it is a widely recognized as one of the most classical rheumatic diseases .they combine autoantigen with autoantibodies in all the body which form immune complexes. [1]The incidence and prevalence of SLE vary greatly around the globe, with North America having the highest estimates at 23.2 per 100,000 person-years and 241 per 100,000 persons, respectively.[2]Since SLE cannot be entirely cured, drugs and a comprehensive approach to treatment can only manage symptoms and slow the disease's course. This makes SLE a significant social and public health issue. Enhancing early SLE diagnosis is essential for successful treatment. In order to improve SLE control, biomarkers—particularly immunological biomarkers—have been developed to aid in improved diagnosis and evaluation of the disease's pathophysiological mechanisms.[3] This review's objectives are to provide an overview of recent developments in our knowledge of the disease's pathophysiology, talk

about the outcomes of using novel targeted medications, and consider potential future treatments that could replace the current standard of care or even be able to treat this severe systemic autoimmune disease.[4]

### 1.2 Etiology of SLE

Although the precise cause of systemic lupus erythematosus (SLE) is unknown, a complex interplay of genetic, environmental, and other variables is probably to blame [5].
**Genetics:** People with Klinefelter syndrome have an increased risk of getting SLE, and some genes may contribute to the condition.

**Environment:** SLE may be brought on by smoking, exposure to UV radiation, virus infections, and certain drugs.

**Immune system:** An autoimmune reaction can occur if the body fails to appropriately eliminate damaged cells, causing the immune system to attack itself.

**Additional factors:** The influence of hormones, ethnic heritage, and epigenetics may not be negligible [6].

### 1.3Epidemiology

Geographical differences are observed in the reported incidence and prevalence of SLE worldwide; North America has the highest incidence and prevalence, Africa the lowest incidence, and Australia the lowest prevalence. The therapy of the condition and its clinical outcome are significantly influenced by factors such as age, gender, and ethnicity. Although SLE is more common in women, men experience a more severe and rapid course of the disease, which leads to a poor prognosis.[7]

### 1.3 Pathophysiology

Notably, compared to individuals without nephritis, SLE patients with lupus nephritis (LN) had higher expression levels of lnc-DC. Assessment of the diagnostic capacity of lncRNAs led to the recognition of GAS5, linc0597 and lnc-DC as specific indicators for SLE. It was discovered that linc0597 and GAS5 together improved diagnostic power. Additionally, it has been proposed that lnc-DC be used as a marker to identify nephritis in SLE patients.[8]Innate and adaptive immune system abnormalities have a role in the pathophysiology of lupus. Typically, the production of autoantibodies against cellular and nuclear antigens results in the development of immunological complexes. Kidney injury caused by complement, particularly through then alternate route has been noted d in mice and human LN. Produced from T- and B-, cells interstitial plasma cells Tubulointerstitial aggregates in the kidney may also create autoantibodies with clonal restrictions. Intrarenal interferon α (IFN-α) expression promotes this kidney-specific autoimmune. TLR7 and TLR8, two Toll-like receptors (TLRs), are ligands for immune complexes. TLR9. TLR7/9 interaction triggers the expression of IFN-α by Dendritic cells that are plasmacytoid, which increases production of antigen-presenting

cells, promotes B-cell autoreactivity development into plasma cells and increases the generation of CD8 memory T cells and CD4 helper T (TH) cells, resulting in increased production of autoantibodies and immunological complex creation. Lupus is associated with abnormalities in B-cell tolerance that result in the generation of autoantibodies. Regulatory T in humans In SLE, cells that typically inhibit the formation of autoantibodies by B and T cells are less in number and have functional defects. [9]

### 1.4 Risk Factors

The following are risk factors for systemic lupus erythematosus (SLE):
**Environmental elements:** UV radiation, crystalline silica exposure, and cigarette smoking Drinking, becoming immunised, and having silicone breast implants are lifestyle factors. Genetic variables include single nucleotide polymorphisms (SNPs), gene polymorphisms, and a family history of autoimmune disorders.
**Hormonal factors:** oestrogen use in postmenopausal women, use of oral contraceptives, and postmenopausal hormone replacement therapy
Additional factors include Helicobacter pylori infection, periodontitis, coeliac disease, allergic rhinitis, and trace minerals including iron and selenium.
SLE is a long-term autoimmune condition that can seriously harm organs and induce inflammation. Joint discomfort, headaches, rashes, fever, hair loss, mouth sores, exhaustion, dyspnoea, and enlarged glands are among the symptoms. Women are more likely than men to have SLE, and young women between the ages of 15 to 44 [10].

## 2. Diagnosis of SLE

**Antibodies to the diagnosis of Sm/RNP**
an ARA criteria for SLE that is very SLE-specific is high titre anti-Sm. despite modest ELISA titre anti-Sm. Assays using immunoprecipitation have been reported. In different illnesses. Antibodies against Sm are seldom observed without anti-RNP since both proteins are ribonucleoproteins connect to common snRNA species inside the spliceosome. More people have anti-RNP, and less tailored to SLE patients. ELISAs that are anti-RNP greater sensitivity than ID, yet ID and ELISA could be comparable to anti-Sm. Thymus substrate from cows is similarly sensitive. To thymus extract from humans for Sm/RNP. The significance of antibody aYnity or isotype is not sure [11].

Systemic lupus erythematosus is diagnosed by combining positive serologies with characteristic clinical symptoms. Numerous sets of classification criteria have been created over time for epidemiological and research objectives due to the great variability of clinical presentations. Certain classification criteria, like the

SLICC classification criteria, can serve as a diagnostic framework to support clinical judgement, though; they are more sensitive and hence especially helpful in early identification [12].

These days, systemic lupus erythematosus is understood to be a collection of clinical symptoms connected to a syndrome. The great masquerader is a non-infectious, non-malignant, non-contagious, and unpredictable condition that affects women approximately ten times more frequently than men when they are of childbearing age. Despite the variability of the condition, several characteristics remain consistent. Debilitating weariness is nearly a constant complaint among SLE patients. African-Americans are three times more likely than European-Americans to suffer from SLE. To diagnose it, a comprehensive clinical history and physical examination are required. For skin symptoms, histological confirmation could be required. It is necessary to conduct laboratory experiments step-by-step. The specificities of antinuclear antibodies (ANA) must be determined if they are found [13].




**(a) Right cheek and ear:** scarring with hyperpigmented border and persistent activity (earlobe keratosis and preauricular erythema). Sores resembling a comedo in the meatus;

**(b) Scalp discoid lupus erythematosus (DLE):** convergence of several erythematous lesions, silvery-white adhering hyper- keratoses, alopecia with scarring, and DLE in the ear;

**(c) On the back, subacute cutaneous lupus erythematosus (SCLE) the arms' extensor surface:**polycyclic annular confluence lesions that are erythematous and with collarette scaling at the inner edge as well as central clearance

**(d)** Joint buckling without erosions in radiologic imaging (Jaccoud) arthropathy [14].

## 3. Treatment of SLE

### 3.1 Traditional medical treatment

#### 3.1.1 Malarial medications

Because it inhibits plasmodial heme polymerase, hydroxychloroquine (HCQ) sulfate—the hydroxylated form of chloroquine—was first employed as an antimalarial drug. Because of its lipophilicity, it can enter lysosomes, which are spherical vesicles containing hydrolytic enzymes that are activated by an acidic pH. Elevated concentrations of HCQ that alkalinises lysosomes can raise pH, reduce lysosome function, and change immunological and metabolic pathways. HCQ blocks DC maturation and TLR7 and TLR9 signalling, which may halt autoantibody synthesis, autophagy, and T-B cell cross-talk. Unless there is a contraindication, it ought to be administered to all SLE patients at a target dose of 5 mg/kg body weight/day. Treat each patient differently based on their risk of flare-ups and retinal toxicity. Individuals with renal disease and prior history of macular or the retina illness, or use of tamoxifen, may necessitate more regular ophthalmologic monitoring.

#### 3.1.2 Hormone-stimulating substances

For many years, the primary treatment for SLE has been glucocorticoids (GCs), and sparing is currently the focus of the illness's treatment. Individuals with moderate-to-severe illnesses have to be dosed according to the participation of each organ and lowered to a maintenance dose of ≤5. mg daily. Intravenous methylprednisolone pulses could be taken into consideration. Anabolic steroids can significant side effects, making it possible for steroid-sparing medications to stop steroid dosing. Fresh Patients who don't react to traditional therapy are advised to try alternative immunosuppressive drugs [15].

### 3.2 Monoclonal antibodies for the treatment of SLE

#### 3.2.1 Rituximab

A monoclonal antibody called rituximab is made to target particular illnesses. It works by precisely attaching itself to B cells that have the CD20 marker on them. The impacted B cells undergo programmed cell death, or apoptosis, as a result of this contact setting off a chain of events. Furthermore, rituximab's effect triggers the immune system's other mechanisms, including phagocytosis, complement-dependent cytotoxicity, and antibody-dependent cellular cytotoxicity, to cause the demise of these cells. Rituximab works by destroying the B cells that make pathogenic antibodies, which prevents these cells from differentiating into plasma cells. This lowers the amount of these dangerous antibodies and aids in the management of the illness. According to the findings, rituximab demonstrateda placebo-like safety profile, with no discernible variations in the incidence of

severe unfavourable events. Within African American and Hispanic groupings patients, rituximab demonstrated a positive outcome. The experiment showed a tendency towards improvement in illness activity for rituximab-treated individuals with moderate to severe SLE. Still, this advancement remained below the threshold of statistical significance, suggesting that rituximab was not inherently better than a placebo in the main results of the clinical process. However, a post hoc study indicated that rituximab might be beneficial. therapy, perhaps leading to a decrease in the frequency of severe flare-ups of SLE. Finally, even though the Although the EXPLORER trial did not prove that rituximab was better for controlling illness, it did offer insightful information. investigating rituximab's tolerance and safety in this particular patient population [16].

### 3.3 Cell-Related Treatments

#### Transplanting Haematopoietic Stem Cells

Originally utilised for life-threatening SLE, the haematopoietic stem cell transplantation (HSCT) technique is a popular treatment in haematology. Thanks to advancements in biotechnology, patients who previously had less severe conditions but were not responding to conventional medication now have the choice to pursue this course of treatment. The goal of this therapy is to replace plasma cells that, as previously mentioned, are resistant to conventional B-cell depletion therapy and are not sensitive to anti-BAFF agents, as well as self-reactive memory T and B lymphocytes, from the recipient's immune system. In contrast, antithymocyte globulin can be used to condition plasma cells in order to prevent graft-versus-host disease (GVHD), which is followed by the regeneration of the haematopoietic system immunological system through transplanting stem cells. For SLE, autologous transplants have been administered to over 300 patients to date. Results have indicated that five years after stopping immunosuppressive medication, 50%–66% of treated individuals experienced remission. The majority of current research indicates that treatment-related mortality is less than 5%, which is a significant decrease from the original studies. Individuals who react can recover their seronegativity for antinuclear antibodies, which is highly challenging to accomplish with conventional therapy, and they are typically symptom-free. It has also been discovered that early HSCT use enhances quality of life and guards against medication toxicity and organ failure [17].

## 4. Result & discussion

An overview of systemic lupus erythematosus (SLE) diagnosis and treatment highlights the significance of a multidisciplinary approach. Clinical criteria and laboratory testing, such as autoantibody profiles, are necessary for an early diagnosis. The goals of treatment are the use of immunosuppressants, corticosteroids, and NSAIDs to control symptoms and stop flare-ups. Novel alternatives for refractory instances are provided by advances in biologic treatments, such as belimumab and anifrolumab. Current research endeavours to enhance comprehension of the illness mechanisms and develop customised treatment approaches, emphasising the necessity of ongoing monitoring and therapeutic modification based on unique patient responses.

**5.Conclusion**

In conclusion, because systemic lupus erythematosus (SLE) is a diverse illness with variable patient presentations, both diagnosis and therapy are still challenging. A comprehensive clinical evaluation is essential for making an accurate diagnosis, and laboratory tests including antinuclear antibody (ANA) screening and other specialised autoantibody assays are also helpful. Effective management requires both a diversified approach and early recognition. Presently, corticosteroids and immunosuppressants are the cornerstone treatments, with the goal of managing symptoms and reducing illness flare-ups. Novel therapeutic options have been made possible by developments in biologic medicines, such as belimumab and rituximab, especially for patients who are refractory. Further investigation into personalised medicine and targeted medicines has the potential to improve patient outcomes. Notwithstanding these developments, there are still issues, such as the requirement for better diagnostic standards and a more thoroughcomprehension of the pathophysiology of the illness. In order to improve patient care, treatment procedures, and ultimately the quality of life for people with SLE, more research is required. It will be crucial to address these issues if the field is to advance and better manage this complex autoimmune disease.

## 5. REFERENCES


1. Quan L, Dai J, Luo Y, Wang L, Liu Y, Meng J, Yang F, You X. The 100 top-cited studies in systemic lupus erythematosus: A bibliometric analysis. Hum VaccinImmunother. 2024 Dec 31;20(1):2387461. doi: 10.1080/21645515.2024.2387461. Epub 2024 Aug 16. PMID: 39149877; PMCID: PMC11328883.
2. Koo M. Systemic Lupus Erythematosus Research: A Bibliometric Analysis over a 50-Year Period. Int J Environ Res Public Health. 2021 Jul 2;18(13):7095. doi: 10.3390/ijerph18137095. PMID: 34281030; PMCID: PMC8295925.
3. Zhang Z. cg05883128 (DDX60) and NR3C2 (CD4 T-cells and B-cells) to Be the Genetic Roots of Systemic Lupus Erythematosus. medRxiv. 2024:2024-01.
4. Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, Paroli M. Advances in the pathogenesis and treatment of systemic lupus erythematosus. International journal of molecular sciences. 2023 Mar 31;24(7):6578.
5. Adhami E. Calculating the etiology of systemic lupus erythematosus. Medical hypotheses. 2004 Feb 1;62(2):237-46.
6. Hess EV, Farhey Y. Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. Current Opinion in Rheumatology. 1995 Sep 1;7(5):371-5.
7. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022 Oct;14(10).

8. Taheri M, Eghtedarian R, Dinger ME, Ghafouri-Fard S. Exploring the Role of Non-Coding RNAs in the Pathophysiology of Systemic Lupus Erythematosus. Biomolecules. 2020 Jun 22;10(6):937. doi: 10.3390/biom10060937. PMID: 32580306; PMCID: PMC7356926.
9. Xagas E, Drouzas K, Liapis G, Lionaki S. Evidence based treatment for lupus nephritis: present perspectives and challenges. Frontiers in Nephrology. 2024 Aug 6;4:1417026.
10. Son M, Kim SJ, Diamond B. SLE-associated risk factors affect DC function. Immunological reviews. 2016 Jan;269(1):100-17.
11. Egner W. The use of laboratory tests in the diagnosis of SLE. Journal of clinical pathology. 2000 Jun 1;53(6):424-32.
12. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. Journal of autoimmunity. 2019 Jan 1;96:1-3.
13. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scandinavian journal of immunology. 2006 Sep;64(3):227-35.
14. Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. DeutschesÄrzteblatt International. 2015 Jun;112(25):423.
15. Costanzo G, Ledda AG, Sambugaro G. State of the art: the treatment of systemic lupus erythematosus. Current Opinion in Allergy and Clinical Immunology. 2024 May 21:10-97.
16. Zavaleta-Monestel E, Arrieta-Vega D, Rojas-Chinchilla C, Campos-Hernández J, García-Montero J, Quesada-Villaseñor R, Anchía-Alfaro A, Arguedas-Chacón S. Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review. Cureus. 2024 Jul;16(7).
17. Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, Paroli M. Advances in the pathogenesis and treatment of systemic lupus erythematosus. International journal of molecular sciences. 2023 Mar 31;24(7):6578.